tetano
Editor, Senior Moderator
Influenza Other Respir Viruses. 2020 Feb 5. doi: 10.1111/irv.12714. [Epub ahead of print] [h=1]Vaccine effectiveness against influenza A(H3N2) and B among laboratory-confirmed, hospitalised older adults, Europe, 2017-18: A season of B lineage mismatched to the trivalent vaccine.[/h]
Rose AMC[SUP]1[/SUP], Kissling E[SUP]1[/SUP], Gherasim A[SUP]2[/SUP], Casado I[SUP]3[/SUP], Bella A[SUP]4[/SUP], Launay O[SUP]5,[/SUP][SUP]6[/SUP], Lazăr M[SUP]7[/SUP], Marbus S[SUP]8[/SUP], Kuliese M[SUP]9[/SUP], Syrj?nen R[SUP]10[/SUP], Machado A[SUP]11[/SUP], Kurečić Filipović S[SUP]12[/SUP], Larrauri A[SUP]2[/SUP], Castilla J[SUP]3[/SUP], Alfonsi V[SUP]4[/SUP], Galtier F[SUP]5,[/SUP][SUP]13[/SUP], Ivanciuc A[SUP]7[/SUP], Meijer A[SUP]8[/SUP], Mickiene A[SUP]9[/SUP], Ikonen N[SUP]14[/SUP], G?mez V[SUP]11[/SUP], Lovrić Makarić Z[SUP]12[/SUP], Moren A[SUP]1[/SUP], Valenciano M[SUP]1[/SUP]; I-MOVE Hospital study team.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Influenza A(H3N2), A(H1N1)pdm09 and B viruses co-circulated in Europe in 2017-18, predominated by influenza B. WHO-recommended, trivalent vaccine components were lineage-mismatched for B. The I-MOVE hospital network measured 2017-18 seasonal influenza vaccine effectiveness (IVE) against influenza A(H3N2) and B among hospitalised patients (≥65 years) in Europe.
[h=4]METHODS:[/h] Following the same generic protocol for test-negative design, hospital teams in nine countries swabbed patients ≥65 years with recent onset (≤7 days) severe acute respiratory infection (SARI), collecting information on demographics, vaccination status and underlying conditions. Cases were RT-PCR positive for influenza A(H3N2) or B; controls: negative for any influenza. "Vaccinated" patients had SARI onset >14 days after vaccination. We measured pooled IVE against influenza, adjusted for study site, age, sex, onset date and chronic conditions.
[h=4]RESULTS:[/h] We included 3483 patients: 376 influenza A(H3N2) and 928 B cases, and 2028 controls. Most (>99%) vaccinated patients received the B lineage-mismatched trivalent vaccine. IVE against influenza A(H3N2) was 24% (95% CI: 2 to 40); 35% (95% CI: 6 to 55) in 65- to 79-year-olds and 14% (95% CI: -22 to 39) in ≥80-year-olds. Against influenza B, IVE was 30% (95% CI: 16 to 41); 37% (95% CI: 19 to 51) in 65- to 79-year-olds and 19% (95% CI: -7 to 38) in ≥80-year-olds.
[h=4]CONCLUSIONS:[/h] IVE against influenza B was similar to A(H3N2) in hospitalised older adults, despite trivalent vaccine and circulating B lineage mismatch, suggesting some cross-protection. IVE was lower in those ≥80 than 65-79 years. We reinforce the importance of influenza vaccination in older adults as, even with a poorly matched vaccine, it still protects one in three to four of this population from severe influenza.
? 2020 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
[h=4]KEYWORDS:[/h] Europe; hospital; influenza; older adults; test-negative design; vaccine effectiveness
PMID: 32022450 DOI: 10.1111/irv.12714
Free full text
Rose AMC[SUP]1[/SUP], Kissling E[SUP]1[/SUP], Gherasim A[SUP]2[/SUP], Casado I[SUP]3[/SUP], Bella A[SUP]4[/SUP], Launay O[SUP]5,[/SUP][SUP]6[/SUP], Lazăr M[SUP]7[/SUP], Marbus S[SUP]8[/SUP], Kuliese M[SUP]9[/SUP], Syrj?nen R[SUP]10[/SUP], Machado A[SUP]11[/SUP], Kurečić Filipović S[SUP]12[/SUP], Larrauri A[SUP]2[/SUP], Castilla J[SUP]3[/SUP], Alfonsi V[SUP]4[/SUP], Galtier F[SUP]5,[/SUP][SUP]13[/SUP], Ivanciuc A[SUP]7[/SUP], Meijer A[SUP]8[/SUP], Mickiene A[SUP]9[/SUP], Ikonen N[SUP]14[/SUP], G?mez V[SUP]11[/SUP], Lovrić Makarić Z[SUP]12[/SUP], Moren A[SUP]1[/SUP], Valenciano M[SUP]1[/SUP]; I-MOVE Hospital study team.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Influenza A(H3N2), A(H1N1)pdm09 and B viruses co-circulated in Europe in 2017-18, predominated by influenza B. WHO-recommended, trivalent vaccine components were lineage-mismatched for B. The I-MOVE hospital network measured 2017-18 seasonal influenza vaccine effectiveness (IVE) against influenza A(H3N2) and B among hospitalised patients (≥65 years) in Europe.
[h=4]METHODS:[/h] Following the same generic protocol for test-negative design, hospital teams in nine countries swabbed patients ≥65 years with recent onset (≤7 days) severe acute respiratory infection (SARI), collecting information on demographics, vaccination status and underlying conditions. Cases were RT-PCR positive for influenza A(H3N2) or B; controls: negative for any influenza. "Vaccinated" patients had SARI onset >14 days after vaccination. We measured pooled IVE against influenza, adjusted for study site, age, sex, onset date and chronic conditions.
[h=4]RESULTS:[/h] We included 3483 patients: 376 influenza A(H3N2) and 928 B cases, and 2028 controls. Most (>99%) vaccinated patients received the B lineage-mismatched trivalent vaccine. IVE against influenza A(H3N2) was 24% (95% CI: 2 to 40); 35% (95% CI: 6 to 55) in 65- to 79-year-olds and 14% (95% CI: -22 to 39) in ≥80-year-olds. Against influenza B, IVE was 30% (95% CI: 16 to 41); 37% (95% CI: 19 to 51) in 65- to 79-year-olds and 19% (95% CI: -7 to 38) in ≥80-year-olds.
[h=4]CONCLUSIONS:[/h] IVE against influenza B was similar to A(H3N2) in hospitalised older adults, despite trivalent vaccine and circulating B lineage mismatch, suggesting some cross-protection. IVE was lower in those ≥80 than 65-79 years. We reinforce the importance of influenza vaccination in older adults as, even with a poorly matched vaccine, it still protects one in three to four of this population from severe influenza.
? 2020 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
[h=4]KEYWORDS:[/h] Europe; hospital; influenza; older adults; test-negative design; vaccine effectiveness
PMID: 32022450 DOI: 10.1111/irv.12714
Free full text